Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program.
| Autor: | Firlik KS; HealthPrize Technologies, Norwalk, CT, USA., Anupindi VR; IQVIA, Health Economics and Outcomes Research, Falls Church, VA, USA., Hayes V; HealthPrize Technologies, Norwalk, CT, USA., DeKoven M; IQVIA, Health Economics and Outcomes Research, Falls Church, VA, USA., Shaikh A; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA., Franchino-Elder J; Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2024 Sep; Vol. 24 (7), pp. 829-843. Date of Electronic Publication: 2024 Jan 04. |
| DOI: | 10.1080/14737167.2023.2296561 |
| Abstrakt: | Objective: To assess the impact of the HealthPrize RespiPoints™ program on treatment adherence and persistence in adults with chronic obstructive pulmonary disease (COPD). Methods: In this retrospective cohort study, program participants and nonparticipants receiving tiotropium bromide (TIO) or TIO and olodaterol between 1 January 2015-31 March 2020 were propensity score matched (PSM), from the linked database of the HealthPrize patient list and IQVIA PharMetrics® Plus. Treatment adherence, persistence, healthcare resource utilization, and costs were compared. Multivariable logistic regression models assessed the odds of adherence (≥80% proportion of days covered [PDC]), adjusted risk of discontinuation, and adjusted total healthcare costs. Results: Program participants ( n = 262) demonstrated a 44% greater adherence during followup than nonparticipants ( n = 262) (mean [standard deviation] PDC: 0.72 [0.27] vs 0.50 [0.36], p < 0.0001). Participants had higher odds of adherence vs nonparticipants (adjusted odds ratio: 2.51; 95% confidence interval: 1.72-3.66, p < 0.0001) and a lower percentage of participants discontinued their index medication (19.85% vs 33.59%, p = 0.0004). Fewer participants were hospitalized during follow-up (13.74% vs 17.56%, p = 0.23); adjusted total medical costs were 24% lower ( p = 0.08). Higher pharmacy costs partially offset lower healthcare costs. Conclusions: Program participants showed improved COPD medication adherence and persistence compared to nonparticipants. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|